INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 43m ago
HOUSE PTR3m ago
SEC 13F3m ago
ROBINHOOD CHAIN3m ago
SEC FORM 4/Grant or awardVerified data

Green Ralph Elias reported VVOS

Director · Vivos Therapeutics, Inc. · Vivos Therapeutics, Inc. — Stock Options (Right to Buy)

Side
A
Value
—
Shares
12.0K
Price
—
Executed
Sep 14, 2026
Disclosed
Oct 26, 2026
Disclosure timeline42 days from execution to publication · legal deadline 2 business days
Sep 14 executedOct 26, 2026 disclosed

VVOS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
31/ 100 · ELEVATED
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+13 / 25

    No reported dollar value · 230.8% of prior position

  • Filing timing+10 / 15

    Disclosed 30 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VVOS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    31
    LF
    Lindsay Mark F.Director
    VVOSVivos Therapeutics, Inc.
    Grant or award
    		A—
    12.0K sh
    		Sep 14, 2026Oct 26, 2026
    traded Sep 14, 2026
    		+42dSEC FORM 4

    Evidence

    50
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$2.39M
    1.78M sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    50
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$1.40M
    1.04M sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    47
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$576K
    430.0K sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    50
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$2.39M
    1.78M sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    43
    SC
    Skaff Michael C10% Owner
    VVOSVivos Therapeutics, Inc.
    Open-market purchase
    		BUY$414K
    308.8K sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001493152-26-048603
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 14, 2026
    Published
    Oct 26, 2026
    Ingested by INSIDER
    Nov 5, 02:09 UTC
    Last re-read
    Nov 5, 02:09 UTC

    Extracted facts

    Filer
    Green Ralph Elias
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Vivos Therapeutics, Inc. — Stock Options (Right to Buy)
    Ticker
    VVOS
    Shares
    12.0K
    Price per share
    $0
    Execution date (reported)
    Sep 14, 2026
    Owned after transaction
    17.2K shares
    Days from execution to publication
    42

    What this establishes

    Green Ralph Elias filed this Form 4 reporting a grant or award of VVOS on Sep 14, 2026. It became public on Oct 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Green Ralph Eliascik:0001835785
    Issuer
    Vivos Therapeutics, Inc.cik:0001716166

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.